SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement
Rhea-AI Summary
SINTX Technologies (NASDAQ: SINT) announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders’ equity of $2.5 million for companies listed on the Nasdaq Capital Market. Nasdaq’s decision is based on SINTX’s Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately $4.83 million. Nasdaq confirmed that the previously disclosed stockholders’ equity deficiency matter is now closed. Management stated that resolving this listing issue supports SINTX’s efforts to strengthen the company while it focuses on commercializing its silicon nitride technologies, expanding its distribution network, and pursuing strategic partnerships aimed at supporting future revenue growth in its medical and advanced ceramics businesses.
Positive
- Regained Nasdaq equity compliance with $4.83 million stockholders’ equity vs. $2.5 million minimum
- Nasdaq deficiency matter closed, removing an overhang on listing status
- Clear focus on commercialization of silicon nitride products and distribution expansion
Negative
- Recent Nasdaq equity deficiency highlights prior balance sheet pressures despite current compliance
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 11 | Business update | Positive | -12.4% | Commercial execution update included purchase orders, revenue outlook and additional financing. |
| Jul 28 | Earnings release date | Neutral | +0.7% | Company scheduled second-quarter results release and investor webcast for August 11. |
| Jul 23 | Strategic program | Positive | -2.6% | Southern Metrics engagement established a program to evaluate strategic corporate-development opportunities. |
| Jun 22 | Purchase orders | Positive | -5.7% | Multiple customers placed more than $3.2 million in advanced ceramics purchase orders. |
| Jun 03 | Private placement | Positive | +7.7% | Private placement and ATM sales generated approximately $5.0 million in equity capital. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive announcements were followed by negative reactions in three of four substantive recent events; the June 3 financing was the exception.
Key Terms
stockholders’ equity financial
silicon nitride technical
fda-cleared regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders’ equity of
Based on SINTX’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately
“We are pleased to have resolved this matter and to have Nasdaq confirm our compliance with the minimum stockholders’ equity requirement,” said Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies. “This is an important step as we continue to strengthen the Company and focus our resources on the commercialization of our silicon nitride technologies and the execution of our growth strategy.”
The Company remains focused on advancing the commercialization of its silicon nitride-based medical products, expanding its distribution network and developing strategic partnerships designed to support future revenue growth.
About SINTX
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SINAPTIC Foot & Ankle Implant System for reconstructive surgery.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s commercialization initiatives, expansion of its distribution network, development of strategic partnerships, growth strategy, future revenue growth and ability to maintain compliance with the continued listing requirements of The Nasdaq Stock Market. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those described in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, except as required by applicable law.
SINTX Contacts:
Investor Relations
Gregg Honigblum, Chief Investment Officer
P: 801-839-3502
E: IR@sintx.com
